Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome Publication Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome A newly approved RNA interference (RNAi) therapy lowers harmful triglyceride (TG) levels in patients with…CertaraMay 7, 2026
Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation Publication Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation This study evaluated how the leukemia drug ziftomenib behaves in the body and whether different…CertaraMay 7, 2026
Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies Publication Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies Population pharmacokinetic (PopPK) and exposure-response modeling were used to support the clinical development of nemtabrutinib,…CertaraMay 7, 2026